MGTX Stock Up on Upbeat Efficacy Data From Parkinson’s Disease Study
MeiraGTx Holdings‘ (NASDAQ: MGTX) clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD) met its primary study objective of safety and tolerability. The stock soared 14.9% in response to the news.
MGTX’s PD Gene Therapy Candidate Betters Sham Treatment
The MGT-GAD-025 study of AAV-GAD for PD demonstrated significant and clinically meaningful improvements from baseline for key efficacy endpoints after 26 weeks of treatment.
Per the data readout, treatment with the candidate resulted in a statistically significant 18-point average improvement from baseline in the UPDRS Part 3 (motor examination) “off” medication score in the high-dose group at week 26. However, no significant change in the sham or low-dose groups was observed.
Additionally, MeiraGTx reported significant dose-dependent improvements from baseline in the disease-specific, patient-reported quality of life PDQ-39 score in both the high and low-dose groups with no significant change in the sham group at 26 weeks.
Year to date, shares of MeiraGTx have plunged 24.1% compared with the industry’s 1.8% decline.
Image Source: Zacks Investment Research
The investigational gene therapy was also found to be generally safe and overall well-tolerated. No serious, AAV-GAD treatment-related adverse events were observed.
Per MGTX, PD is the second most common neurodegenerative disorder after Alzheimer’s, affecting nearly one million people in the United States, with around …
Full story available on Benzinga.com